Slide 1: Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI
Ticker: MRIC Investor Presentation June 9, 2016 Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI © 2016 MRI INTERVENTIONS, INC. | 1
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as “an
Slide 3: MRI Interventions Opportunity
MRI Interventions Opportunity Navigation System Electrode placement for deep brain stimulation for Neurosurgery Laser Ablation for ablation of epileptic foci or Brain Tumors Procedures Brain Tumor Biopsy for deep seated tumors Precise Drug Delivery to target lesions Market potential Market Potential
Slide 4: Leadership
Leadership A History of Med Device Experience Key Management Executive Title Prior Experience Frank Grillo President, CEO Peter Piferi COO Wendelin Maners VP Marketing Robert Korn VP Sales Hal Hurwitz CFO Board of Directors Kimble Jenkins, Maria Sainz Dr. Phillip Pizzo Pascal Girin Timothy Frank Gri
Slide 5: Without ClearPoint, minimally invasive neuro surgery lacks real-time visualization
Without ClearPoint, minimally invasive neuro _ _ _ Conventional Stereotactic Procedure ClearPoint Neuro Procedure No real-time visualization Next generation platform enabling real time, MRI guided, minimally invasive brain surgery © 2016 MRI INTERVENTIONS, INC. | 5
Slide 6: ClearPoint Neuro Navigation System
ClearPoint® Neuro Navigation System Integrated Software, Hardware and Single-Use MRI Safe Devices ClearPoint Software Proprietary software for targeting and trajectory calculation / determination Dicom image based SmartFrame®; SmartGrid® ^ _ _ _ _DZ/_ _ _ _DZ/_ _ enable targeting and trajectory calc
Slide 7: ClearPoint Procedure Overview: Target Selection & Entry Planning
ClearPoint Procedure Overview Target Selection & Entry Planning © 2016 MRI INTERVENTIONS, INC. | 7
Slide 8: ClearPoint Procedure Overview: Trajectory Alignment & Device Insertion
ClearPoint Procedure Overview Trajectory Alignment &Device Insertion SmartFrame® Hand Controller © 2016 MRI INTERVENTIONS, INC. | 8
Slide 9: ClearPoint Procedure Overview: Delivery of Neurological Therapy
ClearPoint Procedure Overview Delivery of Neurological Therapy Drug Delivery1 Electrode Placement Laser Ablation2 (1) Drug Delivery - The SmartFlow® cannula received 510(k) clearance for injection of cytarabine, a chemotherapy drug, to the ventricles or removal of CSF from the ventricles during intr
Slide 10: ClearPoint Hospital Economics
ClearPoint Hospital Economics Increase Patients Better potential patient experience provides hospitals the opportunity to reach additional patient populations that may otherwise forego surgery 65% of eligible DBS patients refuse treatment, due to fear of surgery(1) Established, Attractive Reimbursem
Slide 11: Multi-Therapy MRI-Guided Navigational System
Multi-Therapy MRI-Guided Navigational System Notable Neurosurgeon Supporters Dr. Philip Starr Dr. Paul Larson Dr. Robert Gross Dr. Robert Wharen, Jr. ASSFN Past President UCSF &VA Emory University Mayo Clinic -Jacksonville Published Peer-Reviewed Journal Support Compatible With Multiple Therapies Vi
Slide 12: Patented Intellectual Property
Patented Intellectual Property Close to 100 issued patents around the world 30+ U.S. 50+ OUS 70+ U.S. Patents 45+ OUS Patents Patent Applications Patent Applications Issued patents cover areas such as: MRI-guided surgical systems that include software and devices; the SmartFrame® trajectory guide; o
Slide 13: Patient Impact
Patient Impact D _^ C l e a r Po i nt - E n a b l e d E l e c t ro d e P l a c e m e nt © 2016 MRI INTERVENTIONS, INC. | 13
Slide 14: Patient Benefit
Patient Benefit Minimally Invasive Procedure 7 days after ClearPoint procedure Arrow Indicates Surgery Site INC. | 14
Slide 15: Drug Delivery: Seven Programs Underway
_ W _h _ __ _Delivery Seven Programs Underway Now... Major Challenges in Delivering Drugs to the Brain - Blood brain barrier blocks systemic delivery of almost all drugs 98% of small molecules - Direct injection without ClearPoint is blind, so target is frequently missed - Neopharm Trial - 51% of 57
Slide 16: ClearPoint Drug Delivery
ClearPoint Drug Delivery MR visualization of neuro target MR-guided placement of catheter Therapeutic agent delivered under MR-guidance* 6SHFLDOL]HG_GUXJ_GHOLYHU\_FDQQXODV___FDWKHWHUV Conclusion: The ClearPoint system allows Real-time Convection-enhanced Delivery to be performed with a high level of
Slide 17: The ClearPoint Difference
The ClearPoint Difference With ClearPoint Without ClearPoint (Stereotactic) Direct, high resolution visualization; Performed in No direct visualization; Performed in an operating room an MRI Suite Highly accurate, based on real time images Accuracy to target based only on prior images Patient may be
Slide 18: ClearPoint Revenue Model
ClearPoint Revenue Model B U S I N ES S M O D E L R A ZO R / R A ZO R B L A D E ClearPoint Hardware/Software: $100,000 - $150,000 ASP ClearPoint Disposables: $7,500 (average) ASP per procedure with potentially strong margins Recurring revenue from the sale of disposables Procedures covered by existi
Slide 19: Growing the ClearPoint Footprint
Growing the ClearPoint Footprint Installed Base of 45 sites in the US Emory University Hospital UCSF Medical Center Europe: Warsaw, Poland _ _ _t _ Hospital © 2016 MRI
Slide 20: ClearPoint US Market Opportunity
ClearPoint US Market Opportunity W Epilepsy Brain Tumors Total Prevalence (US) 1,500,000 2,200,000 80,000 (annual diagnosis) Prevalence Drug Treatment 125,000 264,000 Resistant (DTR) 7,500 18,000 Resections: 80,000 Incidence DTR Stereotactic Biopsy: 10,000 Electrode Laser Ablation Biopsy / Laser Abl
Slide 21: ClearPoint Future Opportunities
ClearPoint Future Opportunities Multiple Therapies for Future Growth Patient Treatment Resistant ClearPoint Enabled Current Status Neuro Disorder Population Patient Population Therapy Dystonia 250,000 25,000 DBS Active Use, HDE OCD 3,300,300 100,000 DBS Active Use, HDE Severe Depression 6,000,000 1,
Slide 22: ClearPoint Consumable Revenues
ClearPoint Consumable Revenues Consumables $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2013 2014 2015 2016 © 2016 MRI INTERVENTIONS, INC. | 22
Slide 23: Total Revenue, 2013 - 2015
Total Revenue, 2013 - 2015 $1,600,000 Total Revenue $1,400,000 $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2013 2014 2015 2016 Consumables Capital / Service Other © 2016 MRI INTERVENTIONS, INC. | 23
Slide 24: Cash Flow From Operations
Cash Flow From Operations $0 -$500,000 -$1,000,000 -$1,500,000 -$2,000,000 -$2,500,000 -$3,000,000 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2014 2015 2016 © 2016 MRI INTERVENTIONS, INC. | 24
Slide 25: Commercial Priorities
Commercial Priorities . + Focus on adding surgeons at existing accounts Increase + Target high volume sites, including epilepsy and tumor neurosurgeons within each Utilization account; gain greater share of their procedures, + Add Clinical Specialists and sales reps to commercial team; compensate fo
Slide 26: At the Center of an Emerging Industry Trend
At the Center of an Emerging Industry Trend ClearPoint ClearPoint MRIC is at the point of Electrode Laser Catheter Placement Placement convergence in an industry trend impacting Real Time MRI- some of the most ClearPoint Guided ClearPoint Direct Drug Procedures Performed influential and Delivery in
Slide 27: MRI Interventions, Inc.
Ticker: MRIC MRI Interventions, Inc. Irvine, CA 949.900.6833 mriinterventions.com Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI © 2016 MRI INTERVENTIONS, INC. | 27